Barrow Receives $25 Million Grant for ALS Research
The funding extension helps researchers continue the collection of vital data for future ALS treatment development.
Updated on Oct. 15, 2026 in Stroke
The National Institutes of Health has awarded Phoenix-based Barrow Neurological Institute $25.3 million to extend the ALL ALS research consortium for two years. This funding aims to accelerate drug development for those living with the neurodegenerative disease.
Why it matters
ALS is a progressive condition with an average survival time of three years, making the rapid development of effective treatments a critical priority. This grant ensures that the consortium can continue collecting vital clinical data and biological samples to fuel future therapy research.
The NIH grant represents the largest externally funded research award in the 64-year history of Barrow Neurological Institute. This investment supports the ongoing work of the ALL ALS Consortium, which has enrolled 2,000 participants since its 2023 establishment.
The players
Barrow Neurological Institute
A Phoenix-based neurological research and care center that manages 19 of the 37 research sites in the ALL ALS Consortium.
National Institutes of Health
The primary federal agency responsible for biomedical and public health research in the United States.
The details
The ALL ALS Consortium operates on an open-science model, allowing researchers to share longitudinal data and biological samples from individuals with ALS and healthy controls. Barrow Neurological Institute manages 19 of the 37 clinical research sites involved in the effort, which utilizes a remote participation model to reach patients in rural communities. The research resource is specifically designed to facilitate drug development by providing the clinical insights needed to advance potential therapies.
Timeline
2023: The ALL ALS Consortium was established.
Summer 2024: The first participant was enrolled in the consortium.
October 2026: The NIH awarded $25.3 million in additional funding.
February 2027: ASSESS Study recruitment is scheduled to end.
Health Landscape
The ALL ALS Consortium serves as a hub for large-scale data collection, and this grant update marks a significant expansion of its research capacity. This work follows the establishment of the consortium in 2023 to standardize how clinical and biological data are shared for ALS research.
While this research aims to speed up drug development, patients and families should speak with their neurologist about current clinical trial opportunities or existing treatment options. Tracking updates from research centers like Barrow can help families stay informed on new, evidence-based approaches to care.
The takeaway
The expansion of this research consortium provides a foundation for faster, data-driven drug development for ALS. Patients and caregivers may want to consult their specialist to discuss if participating in current or future research studies is an appropriate path for their specific situation.
Further reading
Learn more about the latest research and advancements in neurodegenerative care in our Stroke section.
Source note: This article includes information reported by KTAR.
